PA
PTEN icon

PharVision Advisers’s Patterson-UTI PTEN Stock Holding History

PharVision Advisers’s Portfolio PTEN Stock Details PTEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
+11,085
New +$124K 1.92% 18
2026
Q1 		– Sell
-31,193
Closed -$191K – 520
2025
Q4 		$191K Buy
31,193
+367
+1% +$2.19K 0.1% 579
2025
Q3 		$160K Buy
+30,826
New +$177K 0.09% 558

Other funds holding PTEN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

PharVision Advisers's PTEN Position: Q2 2026 in Review

PharVision Advisers opened a new position in Patterson-UTI (PTEN) in Q2 2026: 11,085 shares worth $102K. The stake represents 1.92% of the portfolio and ranks #18 among its holdings. This is a return to the name: PharVision Advisers previously reported a position in PTEN as recently as Q4 2025.

PharVision Advisers first reported a position in PTEN in Q3 2025 and has held it in 3 quarters since. The position peaked at $191K in Q4 2025. 439 funds tracked by Wall St. Rank hold PTEN as of Q2 2026.

  • PharVision Advisers held 11,085 shares of Patterson-UTI worth $102K as of Q2 2026.
  • Patterson-UTI was a new PharVision Advisers position in Q2 2026.
  • Patterson-UTI made up 1.92% of PharVision Advisers's portfolio in Q2 2026, its #18 holding.
  • PharVision Advisers first reported a position in Patterson-UTI in Q3 2025 and has held it in 3 quarters since.
  • PharVision Advisers's Patterson-UTI position peaked at $191K in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Patterson-UTI as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.